Report Detail
Global Pet Cancer Therapeutics Market Insights, Forecast to 2025
- RnM2700493 |
- 04 June, 2019 |
- Global |
- 112 Pages |
- QYResearch |
- Pharma & Healthcare
Pet cancer therapeutics are the novel drug molecules that exhibit high potential to reduce the effects of cancer, giving access to comprehensive cancer care with minimum side effects. Cancer therapies aims to permanently eradicate the cancerous cells prevalent in pets. The veterinarian recommends specific treatment program such as targeted therapy and combination therapy or chemotherapy depending on the type of cancer, stage, and nature of the cancer.
The ongoing research activities undertaken by the scientists for the development of novel formulations and therapies is expected to accelerate the market growth.
The global Pet Cancer Therapeutics market is valued at 180 million US$ in 2018 and will reach 330 million US$ by the end of 2025, growing at a CAGR of 7.7% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Pet Cancer Therapeutics market based on company, product type, end user and key regions.
This report studies the global market size of Pet Cancer Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Pet Cancer Therapeutics in these regions.
This research report categorizes the global Pet Cancer Therapeutics market by top players/brands, region, type and end user. This report also studies the global Pet Cancer Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Aratana Therapeutics, Inc
AB Science
Boehringer Ingelheim International GmbH
Zenoaq
Morphogenesis, Inc
VetDC, Inc
Karyopharm Therapeutics, Inc
Rhizen Pharmaceutical SA
Regeneus Ltd.
Oasmia Pharmaceuticals AB
Zoetis
Market size by Product
Chemotherapy
Targeted Therapy
Combination Therapy
Immunotherapy
Market size by End User
Lymphoma
Mast Cell Cancer
Melanoma
Mammary
Squamous Cell Cancer
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Pet Cancer Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Pet Cancer Therapeutics market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Pet Cancer Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Pet Cancer Therapeutics submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Pet Cancer Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Pet Cancer Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Pet Cancer Therapeutics Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Pet Cancer Therapeutics Market Size Growth Rate by Product
- 1.4.2 Chemotherapy
- 1.4.3 Targeted Therapy
- 1.4.4 Combination Therapy
- 1.4.5 Immunotherapy
- 1.5 Market by End User
- 1.5.1 Global Pet Cancer Therapeutics Market Size Growth Rate by End User
- 1.5.2 Lymphoma
- 1.5.3 Mast Cell Cancer
- 1.5.4 Melanoma
- 1.5.5 Mammary
- 1.5.6 Squamous Cell Cancer
- 1.5.7 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Pet Cancer Therapeutics Market Size
- 2.1.1 Global Pet Cancer Therapeutics Revenue 2014-2025
- 2.1.2 Global Pet Cancer Therapeutics Sales 2014-2025
- 2.2 Pet Cancer Therapeutics Growth Rate by Regions
- 2.2.1 Global Pet Cancer Therapeutics Sales by Regions
- 2.2.2 Global Pet Cancer Therapeutics Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Pet Cancer Therapeutics Sales by Manufacturers
- 3.1.1 Pet Cancer Therapeutics Sales by Manufacturers
- 3.1.2 Pet Cancer Therapeutics Sales Market Share by Manufacturers
- 3.1.3 Global Pet Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.2 Pet Cancer Therapeutics Revenue by Manufacturers
- 3.2.1 Pet Cancer Therapeutics Revenue by Manufacturers (2014-2019)
- 3.2.2 Pet Cancer Therapeutics Revenue Share by Manufacturers (2014-2019)
- 3.3 Pet Cancer Therapeutics Price by Manufacturers
- 3.4 Pet Cancer Therapeutics Manufacturing Base Distribution, Product Types
- 3.4.1 Pet Cancer Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Pet Cancer Therapeutics Product Type
- 3.4.3 Date of International Manufacturers Enter into Pet Cancer Therapeutics Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Pet Cancer Therapeutics Sales by Product
- 4.2 Global Pet Cancer Therapeutics Revenue by Product
- 4.3 Pet Cancer Therapeutics Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Pet Cancer Therapeutics Breakdown Data by End User
6 North America
- 6.1 North America Pet Cancer Therapeutics by Countries
- 6.1.1 North America Pet Cancer Therapeutics Sales by Countries
- 6.1.2 North America Pet Cancer Therapeutics Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Pet Cancer Therapeutics by Product
- 6.3 North America Pet Cancer Therapeutics by End User
7 Europe
- 7.1 Europe Pet Cancer Therapeutics by Countries
- 7.1.1 Europe Pet Cancer Therapeutics Sales by Countries
- 7.1.2 Europe Pet Cancer Therapeutics Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Pet Cancer Therapeutics by Product
- 7.3 Europe Pet Cancer Therapeutics by End User
8 Asia Pacific
- 8.1 Asia Pacific Pet Cancer Therapeutics by Countries
- 8.1.1 Asia Pacific Pet Cancer Therapeutics Sales by Countries
- 8.1.2 Asia Pacific Pet Cancer Therapeutics Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Pet Cancer Therapeutics by Product
- 8.3 Asia Pacific Pet Cancer Therapeutics by End User
9 Central & South America
- 9.1 Central & South America Pet Cancer Therapeutics by Countries
- 9.1.1 Central & South America Pet Cancer Therapeutics Sales by Countries
- 9.1.2 Central & South America Pet Cancer Therapeutics Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Pet Cancer Therapeutics by Product
- 9.3 Central & South America Pet Cancer Therapeutics by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Pet Cancer Therapeutics by Countries
- 10.1.1 Middle East and Africa Pet Cancer Therapeutics Sales by Countries
- 10.1.2 Middle East and Africa Pet Cancer Therapeutics Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Pet Cancer Therapeutics by Product
- 10.3 Middle East and Africa Pet Cancer Therapeutics by End User
11 Company Profiles
- 11.1 Aratana Therapeutics, Inc
- 11.1.1 Aratana Therapeutics, Inc Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Aratana Therapeutics, Inc Pet Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Aratana Therapeutics, Inc Pet Cancer Therapeutics Products Offered
- 11.1.5 Aratana Therapeutics, Inc Recent Development
- 11.2 AB Science
- 11.2.1 AB Science Company Details
- 11.2.2 Company Business Overview
- 11.2.3 AB Science Pet Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 AB Science Pet Cancer Therapeutics Products Offered
- 11.2.5 AB Science Recent Development
- 11.3 Boehringer Ingelheim International GmbH
- 11.3.1 Boehringer Ingelheim International GmbH Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Boehringer Ingelheim International GmbH Pet Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Boehringer Ingelheim International GmbH Pet Cancer Therapeutics Products Offered
- 11.3.5 Boehringer Ingelheim International GmbH Recent Development
- 11.4 Zenoaq
- 11.4.1 Zenoaq Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Zenoaq Pet Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Zenoaq Pet Cancer Therapeutics Products Offered
- 11.4.5 Zenoaq Recent Development
- 11.5 Morphogenesis, Inc
- 11.5.1 Morphogenesis, Inc Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Morphogenesis, Inc Pet Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Morphogenesis, Inc Pet Cancer Therapeutics Products Offered
- 11.5.5 Morphogenesis, Inc Recent Development
- 11.6 VetDC, Inc
- 11.6.1 VetDC, Inc Company Details
- 11.6.2 Company Business Overview
- 11.6.3 VetDC, Inc Pet Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 VetDC, Inc Pet Cancer Therapeutics Products Offered
- 11.6.5 VetDC, Inc Recent Development
- 11.7 Karyopharm Therapeutics, Inc
- 11.7.1 Karyopharm Therapeutics, Inc Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Karyopharm Therapeutics, Inc Pet Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Karyopharm Therapeutics, Inc Pet Cancer Therapeutics Products Offered
- 11.7.5 Karyopharm Therapeutics, Inc Recent Development
- 11.8 Rhizen Pharmaceutical SA
- 11.8.1 Rhizen Pharmaceutical SA Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Rhizen Pharmaceutical SA Pet Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Rhizen Pharmaceutical SA Pet Cancer Therapeutics Products Offered
- 11.8.5 Rhizen Pharmaceutical SA Recent Development
- 11.9 Regeneus Ltd.
- 11.9.1 Regeneus Ltd. Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Regeneus Ltd. Pet Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Regeneus Ltd. Pet Cancer Therapeutics Products Offered
- 11.9.5 Regeneus Ltd. Recent Development
- 11.10 Oasmia Pharmaceuticals AB
- 11.10.1 Oasmia Pharmaceuticals AB Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Oasmia Pharmaceuticals AB Pet Cancer Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Oasmia Pharmaceuticals AB Pet Cancer Therapeutics Products Offered
- 11.10.5 Oasmia Pharmaceuticals AB Recent Development
- 11.11 Zoetis
12 Future Forecast
- 12.1 Pet Cancer Therapeutics Market Forecast by Regions
- 12.1.1 Global Pet Cancer Therapeutics Sales Forecast by Regions 2019-2025
- 12.1.2 Global Pet Cancer Therapeutics Revenue Forecast by Regions 2019-2025
- 12.2 Pet Cancer Therapeutics Market Forecast by Product
- 12.2.1 Global Pet Cancer Therapeutics Sales Forecast by Product 2019-2025
- 12.2.2 Global Pet Cancer Therapeutics Revenue Forecast by Product 2019-2025
- 12.3 Pet Cancer Therapeutics Market Forecast by End User
- 12.4 North America Pet Cancer Therapeutics Forecast
- 12.5 Europe Pet Cancer Therapeutics Forecast
- 12.6 Asia Pacific Pet Cancer Therapeutics Forecast
- 12.7 Central & South America Pet Cancer Therapeutics Forecast
- 12.8 Middle East and Africa Pet Cancer Therapeutics Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Pet Cancer Therapeutics Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Pet Cancer Therapeutics . Industry analysis & Market Report on Pet Cancer Therapeutics is a syndicated market report, published as Global Pet Cancer Therapeutics Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Pet Cancer Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
